Day One Biopharmaceuticals, Inc. DAWN
Set alert
21.53 USD 0.00 0.00%
As of Apr 24, 9:30 AM ET
21.53 Day range 21.53
52-week range unavailable
- YTD
- +131.01%
- 1 year
- +172.53%
- Open
- 21.53
- Prev close
- 21.53
- Mkt cap
- 2.22B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.53
- High
- 21.53
- Beta
- -1.75
- Inst. own
- 83.49%
- Dividend
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 8 0 buy · 8 hold · 0 sell
- Strong buy0
- Buy0
- Hold8
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 9
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17195 | -0.28172 – -0.09 | -0.35 | +50.9% | 54.32M | +76.6% | 6 |
| Next quarter | -0.15606 | -0.27635 – -0.03 | -0.29 | +46.2% | 57.13M | +68.5% | 6 |
| Current year | -0.75506 | -1.76 – -0.16 | -1.04 | +27.4% | 240.45M | +52.0% | 7 |
| Next year | -0.04271 | -0.45626 – 0.35 | -0.75506 | +94.3% | 308.14M | +28.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 10, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 9, 2026 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 6, 2026 | Jones Trading | Downgrade | Buy | Hold |
| Mar 6, 2026 | Needham | Downgrade | Buy | Hold |
| Feb 25, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Feb 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 25, 2026 | Needham | Maintained | Buy | Buy |
| Jan 13, 2026 | TD Cowen | Initiated | — | Buy |
| Nov 24, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 24, 2025 | Needham | Reiterated | Buy | Buy |
| Nov 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 6, 2025 | Needham | Maintained | Buy | Buy |
| May 7, 2025 | Needham | Maintained | Buy | Buy |
| Apr 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 25, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 5, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 26, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 26, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 10, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 13, 2025 | Needham | Reiterated | Buy | Buy |
| Jan 7, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 17, 2024 | Jones Trading | Maintained | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 31, 2024 | Needham | Reiterated | Buy | Buy |
| Oct 9, 2024 | Needham | Maintained | Buy | Buy |
| Aug 6, 2024 | JP Morgan | Maintained | Overweight | Overweight |